Introduction
A caesarean scar pregnancy (CSP) is a pregnancy which is partially or completely surrounded by myometrium and fibrous tissue of the scar of the prior lower uterine segment. The term CSP is usually used to describe first trimester pregnancies at the level of the internal os with evidence of myometrial involvement. It is generally becoming accepted that CSP is a precursor of abnormally adherent placenta in the second and third trimester of pregnancy. Some authors have proposed that the term CSP should be used in the first trimester, early placenta accreta in the second, and morbidly adherent placenta in the third trimester of pregnancy. 2 The incidence of CSP has been estimated to range from 1/1800 to 1/2500 of all caesarean deliveries performed. [3] [4] [5] [6] The number of reported cases has increased over recent years, possibly reflecting the rising number of caesareans performed and the more widespread use of transvaginal ultrasonography, leading to the diagnosis being suspected in more cases. [7] [8] [9] [10] [11] There is currently limited knowledge about the risk factors for caesarean scar pregnancy, presenting features, diagnostic criteria and management options. 12 Furthermore, there is no agreement on the best management of caesarean scar pregnancies. This was highlighted by the recent RCOG/AEPU Green-top Guideline, 13 which prioritised the need for research on the optimal management of caesarean scar pregnancy. The three main treatment options are expectant, medical or surgical. Women are counselled about the potential risk and benefits of the different options and are given the choice to either continue with their pregnancy, to watch and wait, or to terminate the pregnancy should it be ongoing.
No population-wide studies of caesarean scar pregnancy have been previously undertaken and the optimum treatment approach is currently unknown. The aim of this study was to use the UK Early Pregnancy Surveillance Service (UKEPSS) platform to identify all women in the UK that were diagnosed with caesarean scar pregnancy. This study describes the cases, diagnosis, management and clinical outcomes.
Methods
This was a national cohort study of women in the UK diagnosed with caesarean scar pregnancy conducted in 86 participating Early Pregnancy Units (EPU) from November 2013 to January 2015. A dedicated online data capture system was designed to facilitate data entry. Baseline data were recorded for age, ethnicity, smoking status at presentation, medical history, parity and caesarean section history. A set of four sonographic criteria was proposed in the study protocol to aid the identification of caesarean scar pregnancy: presence of gestational sac or placental tissue anteriorly at the level of the internal os; evidence of pregnancy invading into the myometrium; evidence of sustained peri-trophoblastic circulation on colour Doppler examination, characterised by high blood-flow velocity (over 20 cm/s) and low impedance (PI < 1) circulation, and negative sliding organ sign (inability to displace the gestational sac from its position using gentle pressure with a transvaginal probe).
The primary outcome was successful treatment following primary management. Success was defined as complete resolution of pregnancy without the need for further intervention following primary management. For instance, if a woman had surgical treatment as the primary management approach and on follow up she was found to have persistent products of conception for which further surgery is performed, this was considered as an additional intervention and failure of primary management. We also recorded complication rates and length of post-treatment follow up. The study outcomes were set by the UKEPSS CSP study steering committee. The UKEPSS general methodology and this study were approved by the North Wales Research Ethics Committee (REC reference 13/WA/0318). Funding for this study was received from the Association of Early Pregnancy Units and Birmingham Women's and Children's Foundation NHS Trust R&D Springboard Fellowship.
Data collection
Cases were identified on a national basis through the monthly e-mailing of UKEPSS reminders. Clinicians were asked to report any woman diagnosed with caesarean scar pregnancy. They were also asked to return cards indicating a 'nil report' so that we could monitor card return rates and confirm the denominator to calculate the incidence rate. The UKEPSS methodology has been described in detail elsewhere.
14 When a clinician returned a card indicating a case, they were then asked to complete an online data collection form asking for details of disease presentation, management and outcomes. All data collected were anonymous. Up to five reminders were sent if forms were incomplete.
Statistical analysis
Incidence was calculated with 95% confidence intervals using denominator data from the most recently available birth registration data as a proxy for the period between February 2014 and February 2015. Success and complication rates are provided for each treatment.
Patient involvement
This study question was prioritised by a nationally representative group of clinicians and patients as a joint UKEPSS initiative comprising the Association of Early Pregnancy Units, the Miscarriage Association, the Ectopic Pregnancy Trust and the Early Pregnancy Clinical Studies Group, and was endorsed by the Royal College of Obstetricians and Gynaecologists. No patients were involved in setting the outcome measures, nor were they asked to advise on interpretation or writing up of results.
Results

Incidence
Eighty-six hospitals with consultant-led early pregnancy units (EPAU) maternity units contributed data to UKEPSS during the study. A total of 102 cases were reported (Figure 1) through the UKEPSS platform between November 2013 and February 2015. We assessed the incidence of CSP over a 12-month period between 7 February 2014 and 6 February 2015. In all, 58 cases of CSP were recorded during that period of time. The estimated number of maternities in the participating units was 390 361, giving an incidence of 1.5 per 10 000 maternities (95% CI 1.1-1.9). Data outcomes were available for 92/102 (90%) of cases. Full treatment outcome data was available for 92 of 102 (90%) reported cases, with a loss to follow-up rate of 9.8%. Of the missing cases, three had planned surgical treatment, two had medical management and one had expectant management; in three cases no data were submitted following diagnosis.
Diagnosis
The mean maternal age at presentation was 35 years (AE 4.7 SD; range 23-45). The mean gestational age (by sonographic measurement) at presentation was 9 weeks (range 6-18). The most common symptom at presentation (Table 1) was vaginal bleeding (44/92, 48%), followed by vaginal bleeding and pain (21/92, 23%), and pain (9/92, 10%). The remaining women were asymptomatic (18/92, 20%). Where severity of bleeding was specified (n = 30), 16 (53%) presented with bleeding reported for less than a period, 6 (20%) with bleeding 'like a period', and 8 (27%) bleeding for 'more than a period'.
Ultrasonography was performed in 85/85 (100%) of women where an investigation was reported; 83 (98%) women had a transvaginal ultrasound scan and 2 (2%) had a transabdominal ultrasound scan. Table 2 shows the frequency of reporting of each of the sonographic criteria proposed in the study protocol. In 50/ 85 (59%) of cases, all four features were present; in 17/85 (20%), three of the four criteria were present; in 12/85 (14%) two of the four criteria were present, and in 6/85 (7%) only one of the four criteria was present on scan.
Additional investigations
A total of 24 women had serial hCG measurements, eight women had MRI assessment, eight women had 3D ultrasonography, and four had diagnostic laparoscopy. Hysteroscopy was used in one case as a combined surgical approach with laparoscopy. None of the cases was investigated by CT scan. These cases were used for the estimation of incidence. *These cases were used for evaluation of risk factors and clinical outcomes.
Outcomes
The treatment outcomes are presented in Table 3 . Of women presenting with CSP, 61% (56/92) had surgical treatment as the primary management of caesarean ectopic pregnancy, followed by expectant management in 23% (21/ 92) and medical management in 16% (15/92). There was no difference in the mean gestation in each group (8 +4 , 9 +1 and 9 weeks for expectant, medical and surgical management, respectively).
Expectant management
Twenty-one (21/92, 23%) women opted for expectant management. The indications for expectant management were maternal request (10/21, 48%) and uncertainty in diagnosis at presentation (5/21, 24%); in 6/21 (29%) the reason was not reported. Fetal cardiac activity was present in 9/21 (43%); of these, 2/9 (22%) pregnancies resolved spontaneously, 5/9 (56%) progressed to livebirths and 1/9 (11%) required second-line surgical treatment in terms of surgical evacuation of retained products of conception. One woman (1/9, 11%) who had a heterotopic pregnancy and opted for expectant management, presented at 17 weeks' gestation in shock and underwent a hysterectomy for a ruptured uterus.
The remaining 12 cases were non-viable: five resolved spontaneously following expectant management; one had second-line medical treatment, and six had second-line surgical treatment.
Medical management
Methotrexate was used in all (15/15, 100%) cases treated by medical management. In 14/15 women, methotrexate was given by the intramuscular route at a dose ranging One woman had an emergency admission with abdominal pain. A transvaginal scan suggested a viable CSP with possible breach of the scar. She underwent a diagnostic laparoscopy, which confirmed a scar pregnancy with uterine rupture. Due to uncontrollable haemorrhage, a laparotomy and repair were performed.
Secondary: Other surgical approaches were used in three cases as second-line treatment: two were emergency procedures and one was planned surgery.
One woman presented with sepsis following medical management of CSP at 13 weeks. She was treated with 90 mg methotrexate followed by a repeat dose 1 week later. She had persistent per vaginal spotting and a scan showed a gestational sac with an embryo and absent fetal heart. She presented 6 weeks later with signs of sepsis. An ultrasound scan showed a fluid area around the site of the scar pregnancy. A laparotomy was performed, which revealed abscess formation at the site of the scar pregnancy; this was excised.
Another woman had a heterotopic pregnancy and opted for expectant management. She presented at 17 weeks with shock and at laparotomy was found to have intra-abdominal bleeding secondary to a ruptured uterus which was not possible to repair. She lost 3500 ml blood and underwent a hysterectomy.
One woman was initially misdiagnosed as having an anembryonic pregnancy and had medical management of miscarriage. She underwent planned secondary surgical management with a combined laparoscopic and hysteroscopic approach. A balloon was inserted and bilateral uterine artery embolisation was performed.
Treatment success
The success rates of expectant, medical and surgical management were 43, 47 and 96%, respectively.
Complications
The rates of complications for expectant, medical and surgical management were 15/21 (71%), 9/15 (60%) and 20/ 56 (36%), respectively.
Bleeding: In all, 10/21 (48%) of women with expectant management had bleeding. Four of 15 cases (27%) were managed medically. Nineteen of 56 cases (34%) who underwent surgical management were reported to have bleeding as a complication.
Uterine artery embolisation (UAE) was performed in three cases. Two cases were initially misdiagnosed as failed pregnancies, one of which was treated with medical management of miscarriage and, due to a persistent mass on scan found in the CS scar, a surgical approach with combined laparoscopy and hysteroscopy was adopted and bilateral UAE was performed. The other had an emergency suction curettage and suffered a 2.5-l blood loss, which was managed with 2 units of blood transfusion, UAE and Foley catheter insertion. The third case is a woman who opted for expectant management and underwent an elective CS at 33 weeks, with subsequent major PPH, managed by bilateral UAE and necessitating caesarean hysterectomy.
Retained products of conception (RPOC): The rate of RPOC following expectant, medical and surgical management was 7/21 (33%), 9/15 (60%) and 2/56 (3.7%), respectively.
Infection: Infection was reported in three cases (3/92, 3%), of which two (2/21, 10%) were in women who had expectant management, and one (1/15, 7%) was following medical treatment.
Collapse: Nineteen per cent (4/21) of women who had expectant management suffered a collapse. There was one case (1/56, 2%) of collapse in the surgical group and none in the medical group.
Uterine scar rupture: There were two cases of uterine scar rupture. One (1/21, 5%) occurred following expectant management. The other case (1/56, 2%) was an emergency presentation with scar rupture in a woman complaining of vaginal bleeding and pain; scar rupture was the indication for surgical management.
Hysterectomy: Four women underwent an emergency hysterectomy, all of whom had expectant management (4/ 21, 19%).
Placenta accreta: There were three cases of placenta accreta, all in women who opted for expectant management (3/21, 14%).
Live births: Five (5/21, 24%) live births resulted from women who opted for expectant management (Table S1 ). Three women had planned caesarean deliveries from 36 weeks' gestation, and the other two women presented with sepsis and underwent pre-term emergency caesarean deliveries. Three (3/5, 60%) pregnancies were complicated by placenta accreta; all three required emergency hysterectomy (3/5, 60%) and two women (2/5, 40%) suffered major obstetric haemorrhage.
Follow up
The median length of follow up in women managed expectantly was 82 days (range 37-174), in women who had medical management 21 days (range 10-31) and following surgical management 11 days (range 4-49).
Discussion
Main findings
This study demonstrates the rarity of caesarean scar pregnancy, estimating the incidence in the UK to be 1.5 per 10 000 maternities overall. This equates to one case every 2 years in a unit delivering 5000 women.
In this study, CSP presented as early as 6 weeks to as late as 18 weeks. The most common symptom at presentation is light painless vaginal bleeding (47%). Transvaginal ultrasonography is the first-line diagnostic tool for caesarean scar pregnancy. The study found that, in the UK, surgical management is used more often than expectant or medical treatment and appears to be associated with a high success rate, low complication rate and short post-treatment follow up.
Strengths and limitations
This is the first population-wide study of caesarean scar pregnancy to be performed in the UK. Data were reported to our study from 86 units across the UK. They include women from various demographics who presented to their local hospitals and were diagnosed and managed according to local protocols. As such, the study reflects a broad representation of UK-wide practice in terms of diagnosis, management and outcomes. Our incidence estimates appear to be lower than those quoted in previous studies. The true prevalence of CSP is likely to be higher than estimated, as some cases will end in the first trimester, either by miscarriage or termination, and go unreported and undiagnosed. 13 Jurkovic et al. 3 and Seow et al. 6 estimated that the prevalence of caesarean scar pregnancy in their local population of women attending the early pregnancy assessment unit as 1:1800 and 1:2216, respectively; however, these estimates were based on a small number of cases in tertiary referral centres.
There is currently no consensus on the diagnostic criteria for CSP. The criteria proposed in the UKEPSS study, which have been previously published, 3, 14 were as follows: location outside the uterine cavity; implantation of the pregnancy into a deficient scar with the gestational sac partially or completely located within the myometrial mantle; evidence of sustained peri-trophoblastic flow on colour Doppler examination; and negative sliding organ sign.
Other published criteria in the literature include those proposed by Timor-Tritsch et al., 7 and consider the following ultrasound features diagnostic: an endometrial and endocervical canal devoid of a pregnancy; a placenta and/ or gestational sac embedded in the hysterotomy scar; in early gestations, a triangular gestational sac that fills the niche of the scar; a thin (1-3 mm) or absent myometrial layer between the gestational sac and bladder; the presence of an embryonic/fetal pole and/or a yolk sac with or without heart activity; the presence of a prominent and at times rich vascular pattern at or in the area of a cesarean delivery scar; and all of the aforementioned in the presence of positive human chorionic gonadotropin (hCG) levels.
The absence of a gold standard test for diagnosis is a key limitation. Current diagnostic criteria have not been subject to validation and are derived from descriptive case series. In our study, 60% of submitted cases reported on all four sonographic features proposed in the UKEPSS study protocol. Doppler assessment for evidence of sustained peritrophoblastic circulation was used in 70% of cases. In the remaining 30%, Doppler assessment was either not performed or not reported, which is of concern. Doppler assessment may help reduce false-positive diagnosis. Reporting centres were invited to submit ultrasound images for review by an expert panel to confirm diagnosis, but few centres provided their images for assessment. It is therefore possible that false-positive cases may have been reported to the UKEPSS study. To minimise the risk of a false-positive diagnosis, the RCOG/AEPU Green-top Guideline 13 has recommended that all non-emergency cases of suspected scar pregnancy be referred to a regional centre to confirm the diagnosis.
Interpretation
Timor-Tritsch et al. 2 provide evidence that the histological appearance of first-trimester scar pregnancy resembles that of abnormally adherent placenta in the second trimester of pregnancy. This supports the long-held view that scar pregnancy may indeed be a precursor of placenta praevia/accreta. There is a possibility that cases with a better outcome remain undiagnosed or unreported. Screening for scar pregnancy is considered controversial due to uncertainty regarding natural history, compliance and accuracy of diagnosis when ultrasound scans are carried out in centres with variable levels of expertise. However, this needs further evaluation through a screening study for women with previous CS, especially for those with multiple CS, in whom the prevalence of the disease is higher.
The exact cause of caesarean scar pregnancy is not well understood. Previous caesarean delivery, previous uterine surgery, multiparity, advanced maternal age and smoking are some of the predisposing factors for CSP that have been proposed in the literature. 15, 16 Studies have shown that the risk of the caesarean scar healing only slightly increases with the number of previous caesarean operations. 17 It has been proposed that the scar surface is increased after many caesarean deliveries, and the anterior uterine wall may be deficient due to fibrosis, poor vascularity and impaired healing. Consequently, the likelihood of implantation into such a scar is increased. 3 At present there are no national guidelines for the counselling and management of CSP. The literature describes a number of surgical approaches for the treatment of CSP, including transcervical surgical evacuation, laparoscopic resection and hysteroscopic resection. Transcervical surgical evacuation performed under ultrasound guidance was the primary surgical approach in our study. Ultrasound guidance is believed to be vital to facilitate safe, successful evacuation of the placental tissue, with less risk of perforation and a reduced surgical time. 18 Surgical treatment had a high treatment success rate (96%). Traditionally, methotrexate was a popular treatment due to the concerns about bleeding with surgical treatment. 19 Greater blood loss with surgical management is not unexpected due to the location of the CSP within the myometrial defect, which has impaired contractility. In 82% of cases where a primary surgical approach was taken, additional haemostatic measures were used at the time of surgery, including misoprostol, syntometrine, insertion of Shirodkar suture and Foley catheter. The method of insertion of a Shirodkar cervical suture has been described previously in the literature.
The effectiveness of a Shirodkar suture in securing haemostasis may be explained by a more effective tamponade of the implantation site achieved by the blood clot. Bleeding into the uterine defect when the cervix is occluded by the suture ensures an even distribution of pressure on the defective myometrium. Oxytocic drugs induce strong contractions of the uterine fundus, which further increase the pressure on the blood vessels at the implantation site and prevent retrograde bleeding into the abdominal cavity through the Fallopian tubes.
Methotrexate was administered in all women undergoing medical management in our study. Less than half of medically managed caesarean scar pregnancies were treated successfully with methotrexate, which is consistent with other study findings. 20 Women wishing to have medical treatment should be informed of the high risk of failure (54%) and the likely need for further treatment with surgical management. This is because one of the main complications associated with medical management is retained products of conception (60% in our study).
This study found that more women opted for expectant management (23%) than medical treatment (16%). The main difficulty in counselling women diagnosed with asymptomatic scar pregnancy is our lack of understanding of the natural history of the condition and our inability to predict the likelihood of different outcomes. Women may choose to have expectant management for various reasons. Some may decide to watch and wait in the hope that the pregnancy resolves spontaneously; in our study, 22% of CSP with live pregnancies resolved spontaneously. Moreover, in cases of diagnostic uncertainty, conservative management may be considered in the first instance. Ross et al. 21 suggest that when a wanted pregnancy is found to be implanted in or on a CS scar very early in gestation, it may be preferable to wait until the placenta has begun to develop and the cord and its insertion site are visible, before making a definitive diagnosis and recommending intervention.
Studies have consistently shown that women with live CSP can have severe outcomes, 3, 7, 9, 15, 19, 22 and there is a widely held view that given these risks, a more active approach to treatment is justified. 23 In our study, there was an overall 4% risk of hysterectomy in women diagnosed with caesarean scar pregnancy. In women who chose to have expectant management, there was an overall 19% risk of hysterectomy; however, in women with viable CSP who opted for expectant management, the risk of hysterectomy was 44%.
Five women in our study had a live birth following planned or emergency caesarean section. One case was in fact a heterotopic pregnancy and the CSP resolved spontaneously early in pregnancy. In the remaining cases, 3/4 (75%) women suffered severe complications including massive obstetric haemorrhage, need for blood transfusion, caesarean hysterectomy and in one case cardiac arrest. Both emergency presentations were with sepsis. Sepsis can complicate these pregnancies given the close proximity of the placenta to the vagina, making it susceptible to ascending infections.
Conclusion
Ultrasound-guided surgical evacuation is a successful treatment with rapid resolution of pregnancy. Expectant management of a caesarean scar pregnancy is associated with a high risk of maternal morbidity, including the risk of hysterectomy due to morbidly adherent placenta.
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